Latest Biotechnology News

Page 66 of 82
Clarity Pharmaceuticals reports that its Cu-SARTATE diagnostic agent significantly outperforms the current standard in detecting neuroendocrine tumours, paving the way for a pivotal Phase III study.
Ada Torres
Ada Torres
5 June 2025
Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.
Ada Torres
Ada Torres
4 June 2025
Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.
Ada Torres
Ada Torres
4 June 2025
Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.
Ada Torres
Ada Torres
3 June 2025
AdAlta Limited has successfully raised $1.1 million through a renounceable rights issue, positioning itself to advance key CAR-T licensing and immunotherapy projects. The capital injection underscores confidence from leadership and investors amid a transformative phase for the biotech company.
Ada Torres
Ada Torres
3 June 2025
Opthea Limited faces a pivotal moment as four board members resign following disappointing Phase 3 trial results and a major workforce reduction. The company’s future hinges on ongoing funding negotiations amid trading suspensions.
Ada Torres
Ada Torres
2 June 2025
Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.
Ada Torres
Ada Torres
30 May 2025
Invion Limited reports no adverse events and early lesion reduction in its Phase I/II non-melanoma skin cancer trial, advancing to dose optimization.
Ada Torres
Ada Torres
29 May 2025
Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.
Ada Torres
Ada Torres
29 May 2025
Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.
Ada Torres
Ada Torres
28 May 2025
INOVIQ Limited clarifies recent share price movements, confirming no undisclosed material information while highlighting an imminent ASCO presentation and provisional patent application tied to its EXO-OC ovarian cancer test.
Ada Torres
Ada Torres
28 May 2025
Neuren Pharmaceuticals posted record 2024 financials driven by DAYBUE royalties and advanced NNZ-2591 into Phase 3 trials, while launching a $50 million share buy-back amid volatile market sentiment.
Ada Torres
Ada Torres
27 May 2025